Sarah Cannon Research Institute
Lorie Patterson has extensive experience in clinical research and management, currently serving as the Manager of Study Operations in the Drug Development Unit at Sarah Cannon Research Institute since December 2008. Prior to this role, Lorie worked as a Clinical Research Associate at Medpace from 2006 to 2008 and as a Clinical Research Coordinator at Nashville Neuroscience Group from 2000 to 2004. Lorie holds a Bachelor of Science degree in Biology from Trevecca Nazarene University and completed earlier education at Davidson Academy from 1987 to 2000.
Sarah Cannon Research Institute
Sarah Cannon Research Institute (SCRI) is one of the world’s leading oncology research organizations conducting community-based clinical trials. In 2022, SCRI formed a joint venture with former US Oncology Research to enhance clinical trial access and availability across the country. Focused on advancing therapies for patients over the last three decades, SCRI is a leader in drug development. It has conducted nearly 700 first-in-human clinical trials since its inception and contributed to pivotal research that has led to the majority of new cancer therapies approved by the FDA today. The combined research network brings together physicians who are actively accruing patients to clinical trials at more than 250 locations in 26 states across the US.